Travere Therapeutics (TVTX) CEO Eric M Dube Sells $13M of Stock
Key Points
- Chief Executive Officer Eric M Dube sold 243,735 shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) at an average price of $53.82 on October 15, 2026, according to a Form 4 filed with the SEC.
- The planned sale reduced the CEO's direct holdings by about 36.0% to 432,886 shares.
- Travere Therapeutics is scheduled to report its next financial results on October 29, 2026, following trailing twelve month revenue of $591.3 million.
Since the trade, $TVTX is down 4.4% to date (from the $52.79 close on Oct 15, 2026).
Get Travere Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $TVTX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Travere Therapeutics, Inc. alert may contain errors. Disclosures
Chief Executive Officer Eric M Dube sold 243,735 shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) on October 15, 2026. According to a Form 4 filed with the SEC, the transactions were executed under a pre-arranged trading plan, bringing the executive's total direct holdings down to 432,886 shares.
TVTX
Travere Therapeutics, Inc.
Inside Eric M Dube's Travere Therapeutics Trade
The CEO unloaded 243,735 shares at an average price of $53.82 per share, netting roughly $13,116,672.15 in the transaction. This planned sale trimmed his stake by 36.02%. The stock closed at $52.79 on the day of the trade.
Other Institutional Activity in Travere Therapeutics
Other large funds made major adjustments to their positions earlier in the year. Jupiter Topco LLC grew its holdings by 5,662,096 shares, ending with 11,324,191 shares worth about $571,758,422. Perceptive Advisors Llc reduced its stake by 389,797 shares, ending with 3,752,574 shares worth about $189,467,467. Nomura Asset Management International Inc trimmed its position by 457,851 shares to hold 2,812,514 shares valued at roughly $142,003,836. Adage Capital Partners GP L.L.C. grew its holdings by 1,592,340 shares, ending with 2,569,356 shares worth about $129,726,788.
Travere Therapeutics, Inc. Stock Up 1.8%
The company recently traded around $50.49, which is 4.4% below its event-day close and 26.5% below its 52-week high of $68.73. Shares sit 123.5% above their 52-week low of $22.59.
Recent Earnings
Travere Therapeutics reported $591.3 million in trailing twelve month revenue with an EPS of -$0.74. The company's next earnings report is slated for October 29, 2026.
Insider Buying and Selling at Travere Therapeutics, Inc.
Earlier on June 12, 2026, insider Roy Baynes bought 4,500 shares at $21.38 per share for a total value of $96,210, and disposed of 4,500 shares in a separate transaction.
Analysts Set New Price Targets
Canaccord Genuity maintained its Buy rating on August 6, 2026, with a target of $70.00. Evercore ISI Group maintained an Outperform rating on August 10, 2026, raising its target to $78.00. Wedbush reiterated an Outperform rating on September 22, 2026, with a $76.00 target. HC Wainwright & Co. reiterated a Buy rating on September 22, 2026, holding its $67.00 target. Guggenheim maintained a Buy rating on September 24, 2026, lifting its target to $89.00. The stock carries a consensus strong buy rating with a mean target price of $75.21 across 14 analyst opinions.
About Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California. The firm develops therapies for people dealing with rare kidney and metabolic conditions. The company employs 497 people and has a market capitalisation of roughly $4.8 billion.
Bottom Line
Investors will look to the upcoming earnings release on October 29, 2026, for further updates on the company's financial trajectory. Form 4 filings remain public records of executive transactions.
Related Filing Alerts
Source: Eric M Dube's Form 4 filing on $TVTX (Oct 15, 2026). Written by software, not financial advice. How we make alerts